National Academies Press: OpenBook
« Previous: References
Suggested Citation:"Acronyms." Institute of Medicine. 2010. Policy Issues in the Development of Personalized Medicine in Oncology: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12779.
×

Acronyms

ACCE Analytic validity; Clinical validity; Clinical utility; and Ethical, legal, and social implications

AHRQ Agency for Healthcare Research and Quality

AML acute myelogenous leukemia

ASCO American Society of Clinical Oncology

CALGB Cancer and Leukemia Group B

CAP College of American Pathologists

CDC Centers for Disease Control and Prevention

CDRH Center for Devices and Radiological Health

CF cystic fibrosis

CHOP cyclophosphamide, doxorubicin, vincristine, prednisone therapy

CLIA Clinical Laboratory Improvement Amendments

CMS Centers for Medicare & Medicaid Services

CPT current procedural terminology

EGAPP Evaluation of Genomic Applications in Practice and Prevention

EGFR epidermal growth factor receptor

EMEA European Medicines Agency

ER estrogen receptor

Suggested Citation:"Acronyms." Institute of Medicine. 2010. Policy Issues in the Development of Personalized Medicine in Oncology: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12779.
×

FDA Food and Drug Administration

FISH fluorescent in situ hybridization

FLT3 FMS-like tyrosine kinase 3

GAPPNet Genomic Applications in Practice and Prevention Network

HER2 human epidermal growth factor receptor 2

HHS U.S. Department of Health and Human Services

HRSA Health Resources and Services Administration

IOM Institute of Medicine

IVDMIA In Vitro Diagnostic Multivariate Index Assay

KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog

MEDCAC Medicare Evidence Development and Coverage Advisory Committee

NCI National Cancer Institute

NIH National Institutes of Health

NLA national limitation amount

OIVD Office of In Vitro Diagnostic Devices

PCR polymerase chain reaction

PET positron emission tomography

PFS progression-free survival

PMA premarket application

PSA prostate-specific antigen

SACGHS Secretary’s Advisory Committee on Genetics, Health, and Society

SACGT Secretary’s Advisory Committee on Genetic Testing

UGT1A1 UDP glucuronosyltransferase 1 family, polypeptide A1

USPSTF U.S. Preventive Services Task Force

Suggested Citation:"Acronyms." Institute of Medicine. 2010. Policy Issues in the Development of Personalized Medicine in Oncology: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12779.
×
Page 71
Suggested Citation:"Acronyms." Institute of Medicine. 2010. Policy Issues in the Development of Personalized Medicine in Oncology: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12779.
×
Page 72
Next: Glossary »
Policy Issues in the Development of Personalized Medicine in Oncology: Workshop Summary Get This Book
×
Buy Paperback | $29.00 Buy Ebook | $23.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

One of the challenges in treating cancer is the disease's complexity and variation among patients. Cancer manifests differently in each patient, so treatments that are effective in one patient may not be effective in another. As cancer care becomes more personalized, subpopulations of individuals will be given preventive or therapeutic interventions based on their susceptibility to a particular disease or their predicted response to a specific treatment. However, before the use of personalized cancer care can reach its full potential, the health care system must resolve a number of technological, regulatory, and reimbursement issues.

To explore these policy challenges, the National Cancer Policy Forum held the workshop Policy Issues in the Development of Personalized Medicine in Oncology in June 2009. Experts provided presentations on the current state of personalized medicine technology, as well as issues in the validation of, regulation of, and reimbursement for the predictive tests that underpin personalized medicine. Participants discussed the obstacles and possible solutions to further developing and using personalized medicine technologies. This document summarizes the workshop.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!